Fennec Pharmaceuticals Inc. (FENC): Looking at Top Wall Street Opinions

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) was one of the hottest stocks as the company shares were 3.59% or 0.18 points lower from last closing price of $5.01, reaching at $4.83. Any clue why there is so much of action in the FENC stock? The share price has dropped in 3 of the last 5 days and is down -25% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -59,100 shares, and in total 32600 shares valued at $157458 were seen changing hands compared with 91700 shares valued at $459417 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the FENC stock is near its bottom.

Fennec Pharmaceuticals Inc. (FENC) shares have notched a 3-month decline of about -25%, but has still tumbled -24.29% year to date. By comparison, the stock sank -61.61% over the past 12 months, while it slipped -27.69% over the 1 month. The company’s market cap is around $96.5M, with its short interest ratio standing at 6.88%.

In the current trading session for FENC, the stock witnessed two major price actions, it rose to a high of $5.065 and was down as much as $4.8 at one point. The high recorded is very low when compared to their 52-week high which is $4.61. The 52-week high is now at -67.77 distance from current price. Their recent low of $14.99 represents a 4.77% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for FENC is $17.75, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

FENC‘s last price was down -37.56% as compared to the average trading price of 50 days recorded at $7.74 while enlarging the period to 200 trading days, the average closing price was $6.37. At present, there are 19.98 million in the total number of common shares owned by the public and among those 16.33 million shares have been available to trade. The percentage of shares being held by the company management was 17.91% while institutions stake was 55%. The company has generated negative returns on equity over the last 12 months (-41.8%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the FENC stock, there is another set of technicals that should be looked into and considered. Its -12.82% decline from moving average of $5.54 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of -0.24 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Fennec Pharmaceuticals Inc. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $17 on shares of Fennec Pharmaceuticals Inc. (NASDAQ:FENC), which corresponds to 251.97% upside potential than its current market price of $4.83 and implies potential despite the recent drop in the price. However, their current target price has fallen from $17 a month ago and is down handily from the consensus target of $17 a quarter ago.

In the last five years, the EPS of the company has been roughly -37.9%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards FENC stock. Deutsche Bank AG trimmed position in the company after it dumped -118.2% or -82,791 shares of its common stock. The hedge fund now owns 15,068 shares worth $72,778, SEC documents show. Geode Capital Management LLC shored up assets in the stock as 35226.58 shares have been purchased, increasing its stake by 12.1% to 39,489 shares which are currently valued at $190,732. In addition, Opaleye Management Inc. recently reported that it now owns 900,000 shares making a total of $4,347,000 based on the recent price. This refelects a change of -9.1% in their ownership.